Last edition
News about
This latest investment brings the total raised by the company to EUR 3.45 million.
AbbVie Partners with Gilgamesh Pharmaceuticals to Develop Therapies for Psychiatric Disorders
AbbVie has signed an option-to-license agreement with Gilgamesh Pharmaceuticals to develop next-generation therapies for psychiatric disorders.
Fulcrum Signs License Deal with Sanofi for Development of Losmapimod in FSHD
Fulcrum Therapeutics has entered into a collaboration and license agreement with Sanofi for the development and commercialization of losmapimod.
The Jackson Laboratory and AbTherx to Boost Therapeutic Antibody Discovery
The Jackson Laboratory (JAX) has forged a strategic partnership with AbTherx to develop and commercialize cutting-edge tools to expedite antibody discovery and derisk the development of vital new therapies.
Biocon Signs Semi-Exclusive Distribution and Supply Deal for with Medix
Biocon Ltd. has signed a semi-exclusive distribution and supply agreement with Medix, a specialty pharmaceutical company in Mexico, for the commercialization of its vertically integrated drug product, Liraglutide (gSaxenda).
Geneticist Mary Dickinson Joins The Jackson Laboratory as Chief Scientific Officer
In her new role, Dr. Dickinson will spearhead JAX's research endeavors, directing scientific strategy and operations to leverage the institution's unique strengths in genetics and genomics.
Terumo BCT Receives FDA Clearance for Innovative Rika Plasma Donation System with iNomi Nomogram
This development marks a key advancement in plasma collection technology, allowing for the determination of plasma collection volume based on an individual donor's height, weight, and hematocrit level at the time of donation.
Sanofi Invests EUR 1 Billion in France to Expand its Biomanufacturing Sites
Sanofi has made an investment of more than EUR 1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) and Lyon Gerland (Rhône).
Ribobay Pharma Offers oligo CRDMO Services with Cytiva FlexFactory Platform
Ribobay Pharma has announced that it will provide cGMP-level oligonucleotide (oligo) CRDMO services to the world using Cytiva's first FlexFactory platform for oligo manufacturing.
The Company continues to expect a decision regarding its 510(k) clearance in July 2024.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy